# PT-141 Clinical Trials and Efficacy Endpoints: The RECONNECT Phase 3 Record > PT-141 clinical trials, documented: the RECONNECT Phase 3 endpoints (FSFI-desire, FSDS-DAO), the 52-week extension, and the published effect-size debate. Every figure cited to its study. The RECONNECT Phase 3 program met its coprimary endpoints — and independent re-analyses call the effects small. Both are true; this page holds them in the same frame. ## The short version The PT-141 clinical trials that mattered for approval were two big studies called RECONNECT, in premenopausal women with low sexual desire. They used standard questionnaires — FSFI and FSDS (the scales trials use to score sexual desire and the distress low desire causes) — and the drug beat placebo on both, by a statistically real but modest amount. A year-long follow-up showed the effect held up. Independent researchers later argued the improvement, while real, is small enough that its everyday meaning is debatable. This page lays out the numbers and that debate side by side. ## The RECONNECT Phase 3 results The PT-141 clinical trials supporting approval were two identical, randomized, double-blind, placebo-controlled Phase 3 studies — the RECONNECT program (studies 301 and 302), `n=1267` premenopausal women with acquired, generalized HSDD [3]. Participants self-administered bremelanotide `1.75 mg` subcutaneously, as needed, over 24 weeks [3]. Both coprimary endpoints were met in both trials [3]. The integrated results: FSFI-desire domain `+0.35` (`P<.001`) and FSDS-DAO item 13 — distress about low desire — `-0.33` (`P<.001`) versus placebo [3]. The [RECONNECT Phase 3 results](/clinical-trials) are the evidentiary core of the approval, and the most-cited numbers in the entire PT-141 record. ## The 52-week extension After the controlled phase, a 52-week open-label extension enrolled 684 women [4]. No new safety signals emerged and the sexual-desire improvements were sustained across up to a year of as-needed use [4]. The principal tolerability issue over the long term was nausea; the full adverse-event rates from this extension (nausea 40.4%, flushing 20.6%, headache 12.0%) anchor the [PT-141 side effects](/side-effects) page [4]. The long-term data is what turned a 24-week efficacy signal into a durable one: the effect did not wash out, and the safety profile stayed stable. That stability — sustained modest benefit, no new safety surprises — is the practical case the approval rests on. ## What the Trials Showed: PT-141 Benefits Stated plainly, the documented **PT-141 benefits** in the approved population are a modest increase in sexual desire and a reduction in the distress caused by low desire, in premenopausal women with HSDD [3][4]. That is the whole approved benefit claim — not improved performance, not a benefit established in men or after menopause. Supporting human work fills in the picture: a 2006 intranasal study showed a single 20 mg dose raised self-reported moderate/high desire versus placebo (`P=0.0114`) [7]; a subcutaneous dose-finding trial across 0.75, 1.25, and 1.75 mg established the Phase 3 dose [8]; Phase 2b responder analyses characterized the proportion of women reaching clinically meaningful improvement [9]; and a patient-experience analysis described how treated women perceived the benefit against the trial-measured effect sizes [11]. An expert evaluation appraised its benefit-risk and place in therapy among options for premenopausal HSDD [12]. ## The effect-size debate The honest counterweight: independent re-analyses (Spielmans 2021, 2024) argue the trial effects on desire and distress, while statistically significant, are **small** and of debatable clinical meaningfulness, and question the outcome measures themselves [3]. A `+0.35` shift on the FSFI desire domain and a `-0.33` shift on a single distress item are real, repeatable, and modest — all at once. This is the central editorial fact of the PT-141 record, and the documentation register exists to hold it without flinching: the trials met their endpoints; the effects are debated as small; both statements are supported. A reader doing due diligence should weigh the `P<.001` significance and the modest magnitude together, not one without the other. ## Field reports versus the measured effect Beyond the trials, PT-141 is widely discussed in non-clinical settings, and the lived-experience picture does not always match the averaged trial numbers. The note below summarizes commonly-described first-hand accounts. It is **not evidence**, carries no PMID, and is fenced off from the cited data above on purpose — read the trial numbers first, the anecdotes second. --- A documentation-grade reading of the bremelanotide record — the approved label and the Phase 3 endpoints logged to source, the effect-size debate left in plain view, and the field reports fenced off from the evidence; not a clinic, not a vendor, not a prescription.